Svetlana Lukienko / Shutterstock.com
Indian pharmaceutical company Dr Reddy’s has agreed a deal to buy global intellectual property rights to a generic version of GSK’s deep vein thrombosis (DVT) treatment Arixtra (fondaparinux sodium) as part of a $17.5 million deal with a partner company.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Dr. Reddy’s Laboratories, GSK, Alchemia, patent, fondaparinux sodium